Skip to main content
. Author manuscript; available in PMC: 2020 Jan 31.
Published in final edited form as: Cancer Immunol Res. 2019 Mar 1;7(3):348–354. doi: 10.1158/2326-6066.CIR-18-0622

Figure 1.

Figure 1

Formats of immunocytokine products in clinical trials. (A) IgG-based biopharmaceuticals bearing IL2, an IL2 variant (IL2v) with reduced CD25 binding, or IL12 (in single-chain format) as payloads. In order to achieve the IgG display of a single-cytokine moiety, researchers adopted “knob-into-hole” technology for the heterodimerization of different antibody heavy chains. (B) Immunocytokines based on antibody fragments (a diabody structure in case of IL2 and scFv fragments for TNF fusions).